1. Home
  2. Africa
  3. Southern Africa
  4. Angola

Sanitation vs. vaccination in cholera control

[Iraq] Basra cholera victims.
There have been 418 cholera cases in 10 provinces of Iraq since 20 August (IRIN)

Only weeks away from the launch in India of an oral cholera vaccine significantly cheaper than available vaccines, community workers and health officials are still sceptical of whether a vaccine is the best way to control cholera, according to the International Vaccine Institute (IVI).



IVI’s director John Clemens told IRIN some water and sanitation programme managers argue that the focus in cholera control should be on safe water access rather than vaccine development.



Cholera is a diarrhoeal infection caused by bacteria found in tainted water and food. The disease generally strikes where water supply, sanitation, food safety, and hygiene are inadequate, according to the World Health Organization (WHO).



Introducing a cheaper vaccine in endemic countries “does not mean diminishing the importance of safe water access”, said IVI’s Clemens. “It is a false dichotomy to pit sanitation against vaccination. Improved water and sanitation is the ultimate, but still far-off, goal for impoverished [endemic] countries. Meanwhile we need to think about inexpensive ways to augment efforts [to control cholera].”



Clemens told IRIN that despite a decade of education about the importance of sanitation and safe drinking water, cholera infections have not declined. “Rather, in recent years there have been unprecedented outbreaks of unprecedented duration [in places] where [cholera] had not been [as serious] a problem in recent years.”



Citing northern Vietnam, Angola and Zimbabwe, IVI’s director said being dogmatic about only vaccinations or sanitation can be deadly. “It is erroneous to think about only one intervention. Progressively, people are thinking about how water sanitation and vaccinations can work together.”



More than 6,000 people died from cholera infections worldwide in 2006 – with nine out of 10 infections reported in Africa – according to WHO. But the international health agency estimates that only about 10 percent of cholera infections are ever reported.



In Zimbabwe from August 2008 up to 4 May cholera killed more than 4,000 and infected at least 97,000, according to WHO.



Cost



People living in countries hardest hit by cholera can ill afford the only internationally licensed vaccine sold as Dukarol, Clemens told IRIN. “Travellers [to endemic areas] are the main users, whereas people most affected by cholera go without.”



Dukarol can cost up to US$30 per dose and requires at least two doses with boosters. IVI’s new vaccine, Shanchol, is expected to cost about $1 per dose and calls for two doses.



Other more affordable oral vaccines are not licensed internationally.



IVI’s oral vaccine is in the final phase of a clinical trial in India where 70,000 patients have been tracked since 2006. The manufacturer is expecting to produce five million doses in the first year of immunisations. IVI’s director said the vaccine has not been tested on infants under one year old.



IVI, based in Seoul, South Korea, started cholera research in 1999 with almost $40 million from The Bill & Melinda Gates Foundation. The institute received an additional $20 million in 2006 to introduce a cholera vaccine in endemic countries.



As the cholera vaccine is licensed only in India, IVI will seek WHO’s approval in late 2009.



pt/np


This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

Share this article
Join the discussion

It was The New Humanitarian’s investigation with the Thomson Reuters Foundation that uncovered sexual abuse by aid workers during the Ebola response in the Democratic Republic of Congo and led the World Health Organization to launch an independent review and reform its practices.

This demonstrates the important impact that our journalism can have. 

But this won’t be the last case of aid worker sex abuse. This also won’t be the last time the aid sector has to ask itself difficult questions about why justice for victims of sexual abuse and exploitation has been sorely lacking. 

We’re already working on our next investigation, but reporting like this takes months, sometimes years, and can’t be done alone.

The support of our readers and donors helps keep our journalism free and accessible for all. Donations mean we can keep holding power in the aid sector accountable, and shine a light on similar abuses. 

Become a member today and support independent journalism

Become a member of The New Humanitarian

Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

Join